Robert A. Blake
Publications by Year
Research Areas
Ubiquitin and proteasome pathways, Protein Degradation and Inhibitors, Estrogen and related hormone effects, Wnt/β-catenin signaling in development and cancer, PI3K/AKT/mTOR signaling in cancer
Most-Cited Works
- In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship.(2003)
- → SU6656, a Selective Src Family Kinase Inhibitor, Used To Probe Growth Factor Signaling(2000)585 cited
- A selective small molecule inhibitor of c-Met kinase inhibits c-Met-dependent phenotypes in vitro and exhibits cytoreductive antitumor activity in vivo.(2003)
- SU6668 is a potent antiangiogenic and antitumor agent that induces regression of established tumors.(2000)
- → USP7 small-molecule inhibitors interfere with ubiquitin binding(2017)334 cited
- → A Novel Tankyrase Small-Molecule Inhibitor Suppresses APC Mutation–Driven Colorectal Tumor Growth(2013)318 cited
- → A cellular model for sporadic ALS using patient-derived induced pluripotent stem cells(2013)302 cited
- → Therapeutic Ligands Antagonize Estrogen Receptor Function by Impairing Its Mobility(2019)218 cited
- → Antibody Conjugation of a Chimeric BET Degrader Enables in vivo Activity(2019)185 cited
- → Antibody-Mediated Delivery of Chimeric BRD4 Degraders. Part 2: Improvement of In Vitro Antiproliferation Activity and In Vivo Antitumor Efficacy(2021)161 cited